Page 425 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 21 Mast Cell Tumors 403

242. Feinmehl R, Matus R, Mauldin GN, et al.: Splenic mast cell tumors 264. Lachowicz JL, Post GS, Brodsky E: A phase I clinical trial evaluat-
in 43 cats (1975-1992), Proc Annu Conf Vet Cancer Soc 12:50(abstr ing imatinib mesylate (Gleevec) in tumor-bearing cats, J Vet Intern
act) 1992. Med 19:860–864, 2005.
VetBooks.ir 243. Macy DW, Reynolds HA: The incidence, characteristics, and 265. Schulman A: Splenic mastocytosis in a cat, California Vet 17:17–
18, 1987.
clinical management of skin tumors of cats, J Am An Hosp Assoc
17:1026–1034, 1981.
244. Buerger RG, Scott DW: Cutaneous mast cell neoplasia in cats: 14 266. Bellamy F, Bader T, Moussy A, et al.: Pharmacokinetics of masi-
tinib in cats, Vet Res Commun 33:831–837, 2009.
cases (1975-1985), J Am Vet Med Assoc 190:1440–1444, 1987. 267. Daly M, Sheppard S, Cohen N, et al.: Safety of masitinib mesylate
245. Wilcock BP, Yager JA, Zink MC: The morphology and behavior of in healthy cats, J Vet Intern Med 25:297–302, 2011.
feline cutaneous mastocytomas, Vet Pathol 23:320–324, 1986. 268. Berger EP, Johannes CM, Post GS, et al.: Retrospective evaluation
246. Holzinger EA: Feline cutaneous masocytomas, Cornell Vet 63:87– of toceranib phosphate (Palladia) use in cats with mast cell neopla-
93, 1973. sia, J Feline Med Surg 20:95–102, 2018.
247. Litster AL, Sorenmo KU: Characterisation of the signalment, clini- 269. Harper A, Blackwood L: Toxicity and response in cats with neo-
cal and survival characteristics of 41 cats with mast cell neoplasia, plasia treated with toceranib phosphate, J Feline Med Surg 19:619–
J Feline Med Surg 8:177–183, 2006. 623, 2017.
248. Molander-McCrary H, Henry CJ, Potter K, et al.: Cutaneous mast 270. Spangler WL, Culbertson MR: Prevalence and type of splenic dis-
cell tumors in cats: 32 cases (1991-1994), J Am Anim Hosp Assoc eases in cats: 455 cases (1985-1991), J Am Vet Med Assoc 201:773–
34:281–284, 1998. 776, 1992.
249. Johnson TO, Schulman FY, Lipscomb TP, et al.: Histopathology 271. Hanson JA, Papageorges M, Girard E, et al.: Ultrasonographic
and biologic behavior of pleomorphic cutaneous mast cell tumors appearance of splenic disease in 101 cats, Vet Radiol Ultrasound
in fifteen cats, Vet Pathol 39:452–457, 2002. 42:441–445, 2001.
250. Garrett LD, Craig CL, Szladovits B, et al.: Evaluation of buffy coat 272. Guerre R, Millet P, Groulade P: Systemic mastocytosis in a cat:
smears for circulating mast cells in healthy cats and ill cats without mast remission after splenectomy, J Small Anim Pract 20:769–772, 1979.
cell tumor-related disease, J Am Vet Med Assoc 231:1685–1687, 2007. 273. Liska WD, MacEwen EG, Zaki FA, et al.: Feline systemic masto-
251. Skeldon NC, Gerber KL, Wilson RJ, et al.: Mastocytaemia in cats: cytosis: a review and results of splenectomy in seven cases, J Am An
prevalence, detection and quantification methods, haematological Hosp Assoc 15:589–597, 1979.
associations and potential implications in 30 cats with mast cell 274. Evans BJ, O’Brien D, Allstadt SD, et al.: Treatment outcomes
tumours, J Feline Med Surg 12:960–966, 2010. and prognostic factors of feline splenic mast cell tumors: a multi-
252. Rodriguez-Carino C, Fondevila D, Segales J, et al.: Expression institutional retrospective study of 64 cases, Vet Comp Oncol 16:
of KIT receptor in feline cutaneous mast cell tumors, Vet Pathol 20–27, 2018.
46:878–883, 2009. 275. Kraus KA, Clifford CA, Davis GJ, et al.: Outcome and prognos-
253. Fondevila D, Rabanal R, Ferrer L: Immunoreactivity of canine tic indicators in cats undergoing splenectomy for splenic mast cell
and feline mast cell tumors, Schweiz Arch Tierheilk 132:409–484, tumors, J Am Anim Hosp Assoc 51:231–238, 2015.
1990. 276. Gordon SS, McClaran JK, Bergman PJ, et al.: Outcome following
254. Buss MS, Mollander H, Potter K, et al.: Predicting survival and prog- splenectomy in cats, J Feline Med Surg 12:256–261, 2010.
nosis in cats with cutaneous mastocytomas of varying histological 277. Bortnowski HB, Rosenthal RC: Gastrointestinal mast cell tumors
grade, Proc Annu Conf Vet Cancer Soc 16:56–57(abstract), 1996. and eosinophilia in two cats, J Am An Hosp Assoc 28:271–275,
255. Dobromylskyj MJ, Rasotto R, Melville K, et al.: Evaluation of 1992.
minichromosome maintenance protein 7 and c-kit as prognos- 278. Halsey CH, Powers BE, Kamstock DA: Feline intestinal sclerosing
tic markers in feline cutaneous mast cell tumours, J Comp Pathol mast cell tumour: 50 cases (1997-2008), Vet Comp Oncol 8:72–79,
153:244–250, 2015. 2010.
256. Melville K, Smith KC, Dobromylskyj MJ: Feline cutaneous mast cell 279. Sabattini S, Giantin M, Barbanera A, et al.: Feline intestinal mast
tumours: a UK-based study comparing signalment and histological fea- cell tumours: clinicopathological characterisation and KIT muta-
tures with long-term outcomes, J Feline Med Surg 17:486–493, 2015. tion analysis, J Feline Med Surg 18:280–289, 2016.
257. Sabattini S, Bettini G: Prognostic value of histologic and immu- 280. Barrett LE, Skorupski K, Brown DC, et al.: Outcome following
nohistochemical features in feline cutaneous mast cell tumors, Vet treatment of feline gastrointestinal mast cell tumours, Vet Comp
Pathol 47:643–653, 2010. Oncol 16:188–193, 2018.
258. Sabattini S, Guadagni Frizzon M, Gentilini F, et al.: Prognostic 281. Arock M: Valent P: Pathogenesis, classification and treatment of
significance of Kit receptor tyrosine kinase dysregulations in feline mastocytosis: state of the art in 2010 and future perspectives, Expert
cutaneous mast cell tumors, Vet Pathol 50:797–805, 2013. Rev Hematol 3:497–516, 2010.
259. Montgomery KW, van der Woerdt A, Aquino SM, et al.: Periocular 282. Bodemer C, Hermine O, Palmerini F, et al.: Pediatric mastocyto-
cutaneous mast cell tumors in cats: evaluation of surgical excision sis is a clonal disease associated with D816V and other activating
(33 cases), Vet Ophthalmol 13:26–30, 2010. c-KIT mutations, J Invest Dermatol 130:804–815, 2010.
260. Lepri E, Ricci G, Leonardi L, et al.: Diagnostic and prognostic fea- 283. Valent P, Arock M, Akin C, et al.: The classification of systemic
tures of feline cutaneous mast cell tumours: a retrospective analysis mastocytosis should include mast cell leukemia (MCL) and sys-
of 40 cases, Vet Res Commun 27(suppl 1):707–709, 2003. temic mastocytosis with a clonal hematologic non-mast cell lineage
261. Turrel JM, Farrelly J, Page RL, et al.: Evaluation of strontium 90 disease (SM-AHNMD), Blood 116:850–851, 2010.
irradiation in treatment of cutaneous mast cell tumors in cats: 35 284. Horny HP, Sotlar K: Valent P: Mastocytosis: state of the art, Patho-
cases (1992-2002), J Am Vet Med Assoc 228:898–901, 2006. biology 74:121–132, 2007.
262. Rassnick KM, Gieger TL, Williams LE, et al.: Phase I evaluation 285. Valent P, Akin C, Escribano L, et al.: Standards and standardiza-
of CCNU (lomustine) in tumor-bearing cats, J Vet Intern Med tion in mastocytosis: consensus statements on diagnostics, treat-
15:196–199, 2001. ment recommendations and response criteria, Eur J Clin Invest
263. Rassnick KM, Williams LE, Kristal O, et al.: Lomustine for treat- 37:435–453, 2007.
ment of mast cell tumors in cats: 38 cases (1999-2005), J Am Vet 286. Ustun C, Deremer DL, Akin C: Tyrosine kinase inhibitors in
Med Assoc 232:1200–1205, 2008. the treatment of systemic mastocytosis, Leuk Res 35:1143–1152,
2011.